Soluble Endoglin (sCD105) as a Novel Biomarker for Detecting Aggressive Prostate Cancer.

Abstract

BACKGROUND/AIM:

We have previously found elevated levels of endoglin (CD105) in the prostate cancer (PC) tissue of men with poor prognosis, compared to men with indolent disease. Herein, we examined whether plasma levels of the soluble form of CD105 (sCD105) differ according to the PC grade at diagnosis.

PATIENTS AND METHODS:

We measured sCD105 in 73 subjects with biopsy-confirmed PC at the Durham, North Carolina, Veteran Affairs Health System. The association between sCD105 and intermediate/high-grade PC risk [Gleason Group (GG) 2-5 vs. 1] was examined using regression models.

RESULTS:

Of 73 men, 27 had low-grade PC and 46 high-grade PC. Higher GG was linked to lower sCD105 (GG1: 6938 pg/ml, GG2-3: 6150 pg/ml, GG4-5: 5554 pg/ml; p=0.012). On multivariable analysis, lower sCD105 was associated with increased high-grade PC risk (ORper 1000 units=1.33, p=0.028).

CONCLUSION:

Lower sCD105 levels were associated with intermediate and high-risk PC. Further investigation is warranted in a larger PC cohort.

• Authors: Adriana C Vidal, Frank Duong, Lauren E Howard, Emily Wiggins, Stephen J Freedland, Neil A Bhowmick, Jun Gong
• Journal: Anticancer research (Anticancer Res) Vol. 40 Issue 3 Pg. 1459-1462 (Mar 2020) ISSN: 1791-7530 [Electronic] Greece
• PMID: 32132043 (Publication Type: Journal Article)
• Copyright: Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Chemical References

• Biomarkers, Tumor
• ENG protein, human
• Endoglin

Topics

• Aged
• Biomarkers, Tumor (blood)
• Cohort Studies
• Endoglin (blood)
• Humans
• Male
• Middle Aged
• Neoplasm Grading
• Prostatic Neoplasms (blood, pathology)